Health condition
Congenital myasthenic syndromes
Congenital myasthenic syndromes are rare genetic disorders of nerve-muscle transmission that can present from birth to adulthood - and choosing the right drug depends entirely on the gene involved.
Key points
What matters most, at a glance.
The essentials in plain English - symptoms, when to seek help, who to see and what treatment looks like.
-
Genetic, not autoimmune: antibody tests are negative and immunosuppression does not help
-
Fatigable weakness of eyes, face, swallowing or limbs, often lifelong but sometimes presenting in adult life
-
Frequently misdiagnosed as seronegative myasthenia gravis or congenital myopathy
-
Gene-specific treatment matters: some subtypes improve with pyridostigmine, others are worsened by it
-
Genetic panels covering CMS genes (CHRNE, RAPSN, DOK7, COLQ and others) secure the diagnosis
Understanding it
About Congenital myasthenic syndromes, and what to do next.
More than 30 genes can disrupt the neuromuscular junction from birth. Severe forms present in infancy, but milder subtypes - DOK7, RAPSN, slow-channel syndromes - can escape notice until the teens or adulthood, presenting as lifelong poor sports performance, droopy eyelids, or limb-girdle weakness that fluctuates. Because the picture resembles autoimmune myasthenia, adults are often treated with steroids and immunosuppression that cannot work, sometimes for years.
The stakes of precise genetic diagnosis are unusually high because therapy is subtype-specific: pyridostigmine helps many forms but aggravates COLQ and DOK7 disease, where salbutamol or ephedrine are the effective agents instead; fluoxetine benefits slow-channel syndrome. A neuromuscular centre will combine neurophysiology with a CMS gene panel and adjust treatment accordingly - transformations are well documented when the right drug finally meets the right gene. If you carry a label of seronegative myasthenia that has never responded convincingly to immunotherapy, asking about congenital myasthenic syndrome testing is a genuinely important question.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them.
Frequently asked
Common questions about Congenital myasthenic syndromes.
Quick, plain-English answers to what people ask us most.
-
What are congenital myasthenic syndromes?
Congenital myasthenic syndromes (CMS) are a group of rare, inherited conditions affecting the connection between nerves and muscles (the neuromuscular junction), causing muscle weakness and fatigue that typically becomes apparent from infancy or early childhood. Unlike myasthenia gravis, which is an acquired autoimmune condition, CMS is caused by inherited genetic mutations affecting proteins essential for normal nerve-to-muscle signal transmission. There are numerous specific genetic subtypes, each with somewhat different features and, importantly, different treatment approaches.
-
What causes congenital myasthenic syndromes?
These conditions are caused by inherited mutations in any of several genes responsible for proteins involved in the complex process of transmitting signals from nerves to muscles at the neuromuscular junction. Inheritance patterns vary depending on the specific gene involved, most commonly autosomal recessive, though some are autosomal dominant. Genetic testing can identify the specific subtype, which is particularly important in this condition group since treatment approaches differ significantly between subtypes.
-
What symptoms do CMS cause?
Symptoms typically include muscle weakness and abnormal fatigue with exertion, often affecting eye and eyelid muscles (causing drooping eyelids or double vision), facial and swallowing muscles, and limb muscles, with symptoms usually apparent from infancy or early childhood. Severity varies considerably between subtypes and individuals, ranging from mild to more significantly disabling. Symptoms characteristically worsen with repeated or sustained muscle use and improve with rest, similar to myasthenia gravis, though the underlying cause and appropriate treatment differ.
-
How is CMS different from myasthenia gravis?
Myasthenia gravis is an acquired autoimmune condition typically developing in adulthood (though it can occur in children too), caused by antibodies attacking the neuromuscular junction, and treated with immune-suppressing therapies. CMS is a genetic condition present from birth, caused by inherited structural or functional defects in specific neuromuscular junction proteins, and is not treated with immunosuppression, since there's no autoimmune process to suppress; instead, treatment is tailored to the specific genetic defect. This distinction is critical, since immunosuppressive treatments effective for myasthenia gravis are not appropriate, and sometimes actively unhelpful, for CMS.
-
How are congenital myasthenic syndromes treated?
Treatment is highly specific to the exact genetic subtype identified, since different CMS subtypes respond to different medications, and a medication helpful for one subtype can sometimes worsen symptoms in another. This is why accurate genetic diagnosis is so important in CMS specifically, guiding a tailored, subtype-appropriate treatment approach. A specialist neuromuscular team with specific experience in CMS typically coordinates this precise, individualised treatment.
-
When should I see a specialist?
See a neurologist if a child or adult has unexplained muscle weakness and fatigue, particularly affecting eye or facial muscles and present from an early age, for specialist assessment and genetic testing to identify the specific subtype. NHS neuromuscular specialist referral can take several weeks to months; a private consultation is typically available within about 2 weeks for earlier specialist assessment.